Published in Vaccine Weekly, June 30th, 2004
According to a study from the United States, "The costimulatory molecule, B7-2, is expressed by various lymphomas, but this level of expression is not sufficient to generate effective anti-tumor immunity in vivo. To determine whether up-regulated expression of the costimulatory molecule, B7-2, leads to more effective anti-tumor immunity in vivo, the A20 murine model of B-cell lymphoma was used. A20 tumor cells express major histocompatibility complex (MHC) I and II molecules and moderate constitutive levels of B7-2."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly